|
|||||
|
|
| 玻璃体腔注射雷珠单抗治疗非AMD脉络膜新生血管 | |
| 引用本文： | 李雨心,南新帅,聂闯,胡莲娜,罗灵.玻璃体腔注射雷珠单抗治疗非AMD脉络膜新生血管[J].国际眼科杂志,2016,16(5):942-944. |
| 作者姓名： | 李雨心 南新帅 聂闯 胡莲娜 罗灵 |
| 作者单位： | 1. 400038 中国重庆市，解放军第三军医大学; 100101 中国北京市，解放军第306医院眼科;2. 100101 中国北京市，解放军第306医院眼科; 230032 中国安徽省合肥市，安徽医科大学;3. 解放军第306医院眼科, 中国北京市,100101 |
| 基金项目： | 国家自然科学基金资助项目(No. 81271016) |
| 摘 要： | 目的：临床观察雷珠单抗( ranibizulab )治疗非年龄相关性黄斑变性( age-related lacular degeneration,AMD)脉络膜新生血管患者的疗效。 方法：回顾性分析2011-07/2015-04间在我院玻璃体腔注射ranibizulab治疗非AMD脉络膜新生血管的疗效及眼部与全身不良反应。治疗前后均进行裂隙灯的检查、最佳矫正视力的测定、荧光素眼底血管造影( fluorescein fundus angiography, FFA)、光学相干性断层扫描( optical coherence tolography,OCT),治疗后分别观察注射次数及术前和术后(末次随访时)患者的最佳矫正视力、黄斑区1 ll直径视网膜最大厚度。 结果：随访6lo~3a,治疗后平均视力(4.77±0.24)与治疗前(4.50±0.34)相比差异具有统计学意义(P<0.01),黄斑区1 ll直径最大厚度(317.62±55.05μl )较术前(421.63±139.37μl )相比差异具有统计学意义( P<0.01)。平均治疗次数为2.6±1.3次。患眼治疗后均未发生眼内炎、青光眼、视网膜脱离、葡萄膜炎等并发症及全身不良反应。 结论：Ranibizulab治疗非AMD脉络膜新生血管有效、不良反应低。 |
| 关 键 词： | 非年龄相关性黄斑变性 脉络膜新生血管 抗血管内皮生长因子 治疗 最佳矫正视力 黄斑厚度 |
| 收稿时间： | 2016/1/26 0:00:00 |
| 修稿时间： | 2016/4/13 0:00:00 |
Clinical observation of intravitreal injection of Ranibizumab for choroidal neovascularization in patients with non- age-related macular degeneration |
|
| Yu-Xin Li,Xin-Shuai Nan,Chuang Nie,Lian-Na Hu and Ling Luo.Clinical observation of intravitreal injection of Ranibizumab for choroidal neovascularization in patients with non- age-related macular degeneration[J].International Journal of Ophthalmology,2016,16(5):942-944. | |
| Authors: | Yu-Xin Li Xin-Shuai Nan Chuang Nie Lian-Na Hu and Ling Luo |
| Institution: | Third Military Medical University, Chongqing 400038, China; Department of Ophthalmology, the 306th Hospital of People''s Liberation Army, Beijing 100101, China;Department of Ophthalmology, the 306th Hospital of People''s Liberation Army, Beijing 100101, China; Anhui Medical University, Hefei 230032, Anhui Province, China;Department of Ophthalmology, the 306th Hospital of People''s Liberation Army, Beijing 100101, China;Department of Ophthalmology, the 306th Hospital of People''s Liberation Army, Beijing 100101, China;Department of Ophthalmology, the 306th Hospital of People''s Liberation Army, Beijing 100101, China |
| Abstract: | AlM:To observe the clinical therapeutic efficacy and safety of intravitreal injection of Ranibizumab for choroidal neovascularization(CNV) in patients with non age-related macular degeneration( non-AMD) . METHODS:Continous cases that had been diagnosed as CNV in non-AMD patients from July 2011 to October 2015 and accepted intravitreal injection of ranibizumab were retrospective analyzed for the efficacy and systemic adverse reactions. The slit lamp examination, best -correct visual acuity ( BCVA ) , fundus fluorescein angiography ( FFA ) and optical coherence tomography ( OCT) were conducted before and after treatment. the injection number, BCVA and the central macular thickness ( CMT ) within diameter of 1mm at macula before and after treatment were observed. RESULTS:The follow-up duration was 6mo to 3a in total 22 patients with 24 eyes. The BCVA was 4. 50 ± 0. 34 at baseline and was improved significantly to 4. 77 ± 0. 24 after treatment(P<0. 01). Mean CMT decreased from 421. 63± 139. 37μm at baseline to 317. 62 ± 55. 05μm at the final follow-up(P<0. 01). The average injection number was 2.6±1.3. None ocular complications and systematic side effects were observed in all cases, such as endophthalmitis, glaucoma, retinal detachment or uveitis. CONCLUSlON:The intravitreal injection of ranibizumab for CNV in non-AMD patients is effective with few side effects. |
| Keywords: | non age-related macular degeneration choroidal neovascularization anti-vascular endothelial growth factor treatment best-correct visual acuity central macular thickness |
| 本文献已被 万方数据 等数据库收录！ | |
| 点击此处可从《国际眼科杂志》浏览原始摘要信息 | |
| 点击此处可从《国际眼科杂志》下载免费的PDF全文 | |